» Authors » Per Jynge

Per Jynge

Explore the profile of Per Jynge including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 29
Citations 265
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Karlsson J, Jynge P
Int J Mol Sci . 2024 Apr; 25(8). PMID: 38673932
Platinum-containing chemotherapeutic drugs are efficacious in many forms of cancer but are dose-restricted by serious side effects, of which peripheral neuropathy induced by oxidative-nitrosative-stress-mediated chain reactions is most disturbing. Recently,...
3.
Karlsson J, Jynge P, Ignarro L
Antioxidants (Basel) . 2023 Mar; 12(3). PMID: 36978857
Disappointing results from the POLAR A and M phase III trials involving colorectal cancer patients on chemotherapy with FOLFOX6 in curative (A) and palliative (M) settings have been reported by...
4.
Karlsson J, Jynge P, Ignarro L
Antioxidants (Basel) . 2021 Dec; 10(12). PMID: 34943040
On 2 July 2021, highly negative results were reported from the POLAR A and M phase III trials in patients with colorectal cancer, treated with an oxaliplatin-based regimen and co-treated...
5.
Karlsson J, Jynge P, Ignarro L
Antioxidants (Basel) . 2020 Oct; 9(10). PMID: 33050459
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by massive inflammation of the arterial endothelium accompanied by vasoconstriction and widespread pulmonary micro thrombi. As a result, due to the...
6.
Jynge P, Skjold A, Falkmer U, Andersson R, Seland J, Bruvold M, et al.
Contrast Media Mol Imaging . 2020 Sep; 2020:3262835. PMID: 32994754
The semistable chelate manganese (Mn) dipyridoxyl diphosphate (MnDPDP, mangafodipir), previously used as an intravenous (i.v.) contrast agent (Teslascan™, GE Healthcare) for Mn-ion-enhanced MRI (MEMRI), should be reappraised for clinical use...
7.
8.
Karlsson J, Jynge P
Acta Oncol . 2017 Dec; 57(6):862-864. PMID: 29243552
No abstract available.
9.
Karlsson J, Andersson R, Jynge P
Transl Oncol . 2017 Jul; 10(4):641-649. PMID: 28668762
Oxaliplatin, in combination with 5-fluorouracil plus folinate (or capecitabine), has increased survival substantially in stage III colorectal cancer and prolonged life in stage IV patients, but its use is compromised...
10.
Karlsson J, El-Saadi W, Ali M, Puskar W, Skogvard P, Engvall J, et al.
Eur Heart J Cardiovasc Pharmacother . 2016 Aug; 1(1):39-45. PMID: 27533964
Aims: The aim of the present study was to examine the feasibility of applying the catalytic antioxidant mangafodipir [MnDPDP, manganese (Mn) dipyridoxyl diphosphate] as a cardioprotective adjunct to primary percutaneous...